10-K: Intelligent Bio Solutions Faces Going Concern Amid Losses

Intelligent Bio Solutions Inc. reported increased net losses and a going concern warning for fiscal year 2025, despite progress in FDA submissions and global market expansion for its fingerprint drug screening system.

Summary

• Intelligent Bio Solutions Inc. reported a net loss of $10,568,733 for the fiscal year ended June 30, 2025, an increase from $10,156,759 in fiscal year 2024.
• The company's cash balance as of June 30, 2025, was approximately $1.02 million, with a working capital deficit of $1,212,419.
• Management believes the current cash and cash equivalents are insufficient to fund operations for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Revenue from sales of goods decreased by $59,249 to $3,052,532 in fiscal year 2025, primarily due to instability in the UK construction sector affecting reader sales.
• Gross profit decreased by $178,767 to $1,246,859, with the gross profit margin declining by 4.96% to 40.85% due to increased direct labor and overhead costs.
• Contribution margin (non-GAAP) increased by $34,718 to $2,129,281, with the contribution margin percentage improving by 2.44% to 69.75%, driven by improved production efficiency and a higher proportion of high-margin cartridge sales.
• Government support income significantly increased by $392,125 to $816,901, mainly from R&D tax refunds and the unwinding of grant income.
• Development and regulatory approval expenses rose by $722,707 to $2,396,513, reflecting increased R&D activities, clinical trials, and the FDA 510(k) clearance submission.
• An impairment loss of $220,062 was recognized for construction in progress (CIP) assets related to a manufacturing facility in Australia, as these assets had no alternative use and were deemed for disposal.
• The company successfully submitted its 510(k) premarket notification to the U.S. FDA for its Intelligent Fingerprinting System in December 2024.
• Clinical studies for the IFP System showed strong results: 82.2% sensitivity, 100% specificity, and 94.1% accuracy in a method comparison study, and pharmacokinetic data closely aligned to blood for codeine detection.
• The development of the Biosensor Platform Technology (BPT) has been postponed indefinitely due to the liquidation of the former licensor and the reversion of intellectual property rights to the University of Newcastle.
• The company expanded its global reach by launching new localized websites in Arabic, Italian, and Spanish, and integrating Latin American Spanish and Arabic into its IFP System.
• A new US patent was granted for the Intelligent Fingerprinting Drug Screening Cartridge, bringing the total active US patents to six.
• Over 1,000 Intelligent Fingerprinting Drug Screening Readers were installed with customers as of June 30, 2024, and 115 new customer accounts were added in fiscal year 2025.
• Material weaknesses in internal control over financial reporting were identified for fiscal years 2024 and 2025, with ongoing remediation efforts including hiring additional personnel and implementing new accounting systems.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including increasing net losses and a going concern warning, indicating severe liquidity issues. While there are positive operational developments like FDA submission progress, new patents, and market expansion efforts for the core product, these are overshadowed by the immediate financial instability, stalled development of another key platform, and identified material weaknesses in internal controls. The need for continuous capital raises and the uncertainty surrounding grant repayment terms further contribute to a negative financial outlook.

Positives

• Successfully raised approximately $4.60 million in fiscal year 2025 through an underwritten public offering and an At-the-Market (ATM) offering, bolstering liquidity.
• Achieved significant regulatory milestones, including the submission of a 510(k) premarket notification to the U.S. FDA for the IFP System in December 2024.
• Completed a method comparison study for the IFP System demonstrating high accuracy (94.1%), sensitivity (82.2%), and specificity (100%), validating its potential for workplace drug testing.
• Pharmacokinetic (PK) study showed strong initial results, confirming fingerprint sweat as a reliable sample matrix for drug detection, with data closely aligned to blood for codeine.
• Expanded global market presence by launching new localized websites in Arabic, Italian, and Spanish, and integrating these languages into the IFP System.
• Granted a sixth active U.S. patent for its Intelligent Fingerprinting Drug Screening Cartridge, strengthening intellectual property protection.
• Installed over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers by June 30, 2024, indicating growing product adoption.
• Secured new distribution partnerships with Spirit Group in Australia and QabasTech in Saudi Arabia, enhancing market reach.
• Added 115 new customer accounts during fiscal year 2025, demonstrating continued customer acquisition.
• Improved non-GAAP contribution margin percentage by 2.44% to 69.75%, reflecting better production efficiency and sales mix towards high-margin cartridges.
• Reduced selling, general and administrative expenses by $374,579 in fiscal year 2025, indicating some cost efficiency improvements.

Negatives

• Incurred a net loss of $10,568,733 for fiscal year 2025, an increase from the $10,156,759 loss in fiscal year 2024, indicating continued unprofitability.
• The company's cash balance of $1.02 million as of June 30, 2025, is deemed insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• Revenue from sales of goods decreased by $59,249 in fiscal year 2025, primarily due to instability in the UK construction sector.
• Gross profit decreased by $178,767, and the gross profit margin declined by 4.96% to 40.85%, mainly due to increased direct labor costs and minimum wage increases for factory staff.
• Development of the Biosensor Platform Technology (BPT) has been postponed indefinitely due to intellectual property rights reverting to the University of Newcastle following the licensor's liquidation, with an unknown timeline for new licensing.
• Recognized an impairment loss of $220,062 on construction in progress (CIP) assets for a manufacturing facility in Australia, as these assets had no alternative use and are slated for disposal.
• Identified material weaknesses in internal control over financial reporting for both fiscal years 2024 and 2025, indicating deficiencies in financial reporting processes and oversight.
• An amount of $2,172,108 remains payable to the Australian Government from a grant, with repayment terms not yet finalized, posing a potential liquidity risk if unfavorable terms are imposed.
• Increased development and regulatory approval expenses by $722,707, contributing to the overall net loss.

Risks

• Need to raise additional capital to fund operations in the future; failure to do so may lead to cessation of operations or asset sales, with potential for significant stockholder dilution.
• Independent registered public accounting firm included an explanatory paragraph relating to the company's ability to continue as a going concern.
• Significant losses incurred since inception and continued losses, with no assurance of achieving significant revenues or profitability.
• Reliance on third parties to perform certain confirmatory tests for the IFP System, with few alternatives, posing risks of service disruption or increased costs.
• Dependence on a limited number of single-source suppliers for critical IFP System components, making the company vulnerable to supply shortages and price fluctuations.
• Results may be impacted by changes in foreign currency exchange rates, as a majority of sales are denominated in foreign currencies.
• Failure to retain or increase marketing and sales capabilities, or to develop broad awareness of products cost-effectively, may hinder revenue growth.
• Ability to achieve profitability depends on maintaining or increasing gross margins on product sales, which may be challenging due to various factors.
• Inability to accurately forecast customer demand and manage inventory could lead to write-downs, write-offs, or damage to reputation.
• Damage or inoperability of the single manufacturing facility in Cambridge, UK, could interrupt research, development, and supply of products.
• Reliance on third-party distributors for product distribution; their failure to effectively market or comply with laws could harm operating results.
• If third-party payors do not provide coverage and reimbursement for IFP products, business and prospects may be negatively impacted.
• Non-United States governments may impose strict price controls, adversely affecting future profitability.
• The IFP System, including its software, may contain undetected errors, limiting product provision and diminishing attractiveness.
• Reliance on proper function, security, and availability of information technology systems and data; breaches or disruptions could materially affect business.
• Future performance depends on continued engagement of key management team members; loss of key personnel could negatively impact business.
• Inability to attract and retain highly skilled managerial, scientific, and technical personnel may hinder successful business model implementation.
• Failure to comply with applicable regulatory quality system regulations by the company or manufacturers could interrupt operations.
• Subject to healthcare fraud and abuse laws and regulations; violations could lead to substantial penalties and adverse publicity.
• Product liability suits, whether meritorious or not, could result in expensive litigation, substantial damages, and increased insurance rates.
• Violation of laws protecting patient health information confidentiality could lead to civil or criminal penalties and harm reputation.
• Potential for litigation or other legal proceedings that could adversely affect business, results of operations, and reputation.
• Changes to U.S. tax laws (e.g., One Big Beautiful Bill Act) and potential changes to tariff policies could adversely affect financial condition.
• Regulatory clearance/approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying product launches.
• Clinical data obtained may not meet required objectives, delaying or preventing additional regulatory clearance.
• Inability to complete required clinical evaluations or significant delays could impair the business plan.
• Reliance on third parties to conduct clinical evaluation work; their non-compliance with good clinical practice could adversely affect product development.
• Ability to obtain, maintain, and protect intellectual property rights is crucial for success; failure to do so could impair competitive position.
• Limited foreign intellectual property rights may prevent the company from stopping third parties from practicing inventions or selling infringing products abroad.
• Claims challenging the invention of intellectual property used by the company could lead to lawsuits and loss of valuable rights.
• Liquidation of Life Science Biosensor Diagnostics Pty Ltd (LSBD) and reversion of Biosensor IP to the University of Newcastle poses risks of extended delays or unfavorable licensing terms.
• Reliance on confidentiality agreements that could be breached or difficult to enforce, allowing third parties to use intellectual property to compete.
• Failure to respond quickly to technological or other developments could render products uncompetitive and obsolete.
• Fluctuations in foreign currency values may materially adversely affect investment.
• Subject to laws and regulations governing business conduct (e.g., FCPA); non-compliance could result in costly programs, fines, or penalties.
• Changes in economic, political, or social conditions or government policies in target markets could have a material adverse effect.
• Inability to repay the grant received from the Australian Government on time, especially if unfavorable repayment terms are imposed.
• Failure to maintain compliance with Nasdaq Capital Market listing requirements could lead to delisting, affecting financing and stock liquidity.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting, affecting investor confidence.
• Limited accounting personnel and supervisory resources as an emerging growth company may hinder adequate execution of accounting processes and internal controls.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or products.
• Market price of common stock may be significantly volatile due to various factors, including clinical trial results, regulatory approvals, and financial performance.

Future Outlook

The company plans to increase market share in the United Kingdom and mainland Europe, commence sales and distribution in Australia, New Zealand, and the Asia Pacific Region, and establish necessary infrastructure and regulatory compliance. A key focus is securing FDA 510(k) clearance for the IFP System's opiate test system for codeine in the U.S., with subsequent expansion for additional drugs. Research is planned to broaden IFP System capabilities for new drugs and indications, facilitating expansion into point-of-care medical testing. The company also intends to expand into new customer segments like major sporting organizations, law enforcement, and commercial airlines, and develop a strategic network of distributors. Development of the Biosensor Platform Technology (BPT) is postponed until licensing arrangements with the University of Newcastle can be finalized after the former licensor's liquidation. The company expects development and regulatory expenses to increase in future periods due to planned additional studies for drugs of abuse. Management aims to increase cost efficiency and streamline the business.

Management Comments

• Management believes there is material risk that its cash and cash equivalents as of June 30, 2025, of approximately $1.02 million, may be insufficient to allow the Company to fund its current operating plan through at least the next twelve months from the issuance of these consolidated financial statements.
• The Company will be required to raise additional funds during the next 12 months.
• We aim to increase our cost efficiency as we streamline the business and implement changes, delivering increased value for investors.

Industry Context

The company operates within the rapidly growing Point of Care (POC) diagnostics and drug screening markets. The global POC diagnostics market is projected to reach $75.46 billion by 2027, with lateral flow assays, the technology underpinning the IFP System, dominating this growth. The global drug screening market is estimated to reach $19.5 billion by 2029, with the employer and workplace drug testing segment also showing steady growth. The increasing global prevalence of drug misuse and the demand for faster, non-invasive testing solutions support the company's mission. The company's focus on expanding its fingerprint sweat-based technology into broader medical diagnostics aligns with the trend of leveraging core lateral flow platforms for diverse diagnostic needs, offering speed, accessibility, and efficiency compared to traditional methods.

Comparison to Industry Standards

• The IFP System's method comparison study demonstrated 82.2% sensitivity, 100% specificity, and 94.1% accuracy, which are strong performance characteristics for a drug screening system, positioning it competitively against conventional urine and oral fluid tests.
• Compared to traditional urine and oral fluid drug testing, the IFP System offers competitive advantages such as non-invasive sample collection (seconds vs. hours), hygienic and non-biohazardous disposal, and automated, unambiguous results from the DSR-Plus reader, reducing human interpretation error.
• The IFP System's unique 16-hour detection window makes it ideal for assessing fitness for work at the time of testing, a key differentiator in the employer and workplace drug testing segment.
• While the company faces competition from major medical device companies with greater resources, its patented fingerprint sweat technology provides a unique competitive advantage in the lateral flow assay segment, which is a high-growth category within POC diagnostics.
• The company's manufacturing facility in Cambridge, UK, has a capacity of 90,000 cartridges per month, significantly exceeding its current production rate of 12,000 cartridges per month, indicating ample room for scaling production to meet future market demand, aligning with industry growth projections.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any pending legal proceeding, nor is its property the subject of a pending legal proceeding that is believed to be material to the financial condition of the business.

Related Party Transactions

• There were no Related Party Transactions since the beginning of the last fiscal year, and there are no currently proposed transactions.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises and potential loss of investment due to substantial doubt about the company's ability to continue as a going concern. The increased net losses and declining revenue/gross profit directly impact shareholder value. However, progress in FDA clearance and market expansion could offer long-term upside if financial stability is achieved.
• **Employees:** The company's financial instability and going concern warning could create uncertainty regarding job security. However, the company is actively hiring accounting and finance personnel as part of remediation efforts, and employment agreements for key executives have been amended to enhance severance benefits.
• **Customers:** Benefit from the continued development and expansion of the non-invasive IFP System, including new language integrations and distribution partnerships, which aim to improve accessibility and usability of drug screening solutions. However, potential supply chain disruptions or operational interruptions due to financial issues could impact product availability.
• **Suppliers:** The company's reliance on a limited number of single-source suppliers for critical components creates interdependence. Financial instability could pose payment risks to suppliers, while supplier issues could impact the company's production.
• **Creditors:** Face increased risk due to the company's going concern warning and working capital deficit. The $2.17 million payable to the Australian Government from a grant, with unfinalized repayment terms, represents a significant liability.

Next Steps

• Continue efforts to secure FDA 510(k) clearance for the IFP System's opiate test system for codeine in the U.S., followed by planned initial launch and additional FDA clearances for other drugs.
• Initiate research to broaden the capabilities of the IFP System to test for additional drugs and indications, expanding into point-of-care medical testing.
• Expand the IFP System into new customer segments, including major sporting organizations, law enforcement, and commercial airlines.
• Develop a strategic network of distributors throughout the APAC Region, Europe, and North America to distribute IFP Products.
• Finalize licensing arrangements related to the Biosensor Platform Technology (BPT) with the University of Newcastle once the liquidation of LSBD is complete.
• Conduct future studies for additional drugs of abuse, which will likely increase development and regulatory expenses.
• Continue to implement measures to remediate identified material weaknesses in internal control over financial reporting, including hiring additional qualified accounting and finance personnel and enhancing controls.
• Negotiate and finalize repayment terms for the $2,172,108 grant amount payable to the Australian Government.
• Monitor and upgrade internal controls as necessary or appropriate for the business.
• Continue exploring fundraising opportunities to meet future capital requirements and fund operations.

Key Dates

Recommendation

While Intelligent Bio Solutions Inc. operates in a high-growth medical technology sector with a promising, patented product (IFP System) and has achieved notable operational milestones like FDA submission progress, new patents, and expanded distribution, the severe financial challenges cannot be overlooked. The company's increased net losses, substantial doubt about its ability to continue as a going concern, and reliance on continuous capital raises present significant short-to-medium term risks. The stalled Biosensor Platform development and identified material weaknesses in internal controls add to the uncertainty. A seasoned investor would likely 'hold' to monitor the effectiveness of the company's remediation efforts for internal controls, the outcome of the FDA clearance process, and its ability to secure future funding on favorable terms without excessive dilution. This position acknowledges the high-risk, high-reward nature of the investment, balancing the innovative potential against the immediate financial instability.

Keywords

Medical Technology, Drug Screening, Fingerprint Diagnostics, Point-of-Care Testing, FDA Clearance, Non-Invasive Testing, Biotechnology, Diagnostics, Healthcare, Nasdaq, INBS, SEC Filing, Annual Report